2 presentations found for upcoming ESC 2021 meeting: https://digital-congress.escardio.org/ESC-Congress
Reduction in the risk of MACE with apabetalone in patients with recent acute coronary syndrome and diabetes according to NAFLD fibrosis score: exploratory analysis of the BETonMACE trial
Presenter: Peter Toth (CGH Medical Center and The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease - Baltimore, United States of America)
Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
Presenter: Dean Gilham (Resverlogix Corp. - Calgary, Canada)